Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease

2017 ◽  
Vol 32 (11) ◽  
pp. 1600-1609 ◽  
Author(s):  
Yi-Ting Hsu ◽  
Ya-Gin Chang ◽  
Ching-Pang Chang ◽  
Jian-Jing Siew ◽  
Hui-Mei Chen ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Behavioral Responses ◽  
Aminobutyric Acid ◽  
Gamma Aminobutyric Acid ◽  
Pharmacological Agents

Huntington's disease: Treatment with dipropylacetic acid and gamma-aminobutyric acid

Neurology ◽  
1976 ◽  
Vol 26 (1) ◽  
pp. 61-61 ◽  
Author(s):  
I. SHOULSON ◽  
R. KARTZINEL ◽  
T. N. CHASE
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Aminobutyric Acid ◽  
Gamma Aminobutyric Acid ◽  
Disease Treatment

Enhanced striatopallidal gamma‐aminobutyric acid (GABA) A receptor transmission in mouse models of huntington's disease

2019 ◽  
Vol 34 (5) ◽  
pp. 684-696 ◽  
Author(s):  
Tamara Perez‐Rosello ◽  
Simon Gelman ◽  
Geoffrey Tombaugh ◽  
Roger Cachope ◽  
Vahri Beaumont ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Mouse Models ◽  
Aminobutyric Acid ◽  
Gamma Aminobutyric Acid ◽  
Gaba A

scholarly journals Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31

2021 ◽  
Author(s):  
Danielle A. Simmons ◽  
Brian D. Mills ◽  
Robert R. Butler III ◽  
Jason Kuan ◽  
Tyne L. M. McHugh ◽  
...  
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Treatment Response ◽  
Diffusion Tensor ◽  
Disease Onset ◽  
Therapeutic Effects ◽  
Plasma Cytokine ◽  
Cytokine Levels ◽  
Pharmacodynamic Biomarkers

AbstractHuntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomarkers. Multi-modal magnetic resonance imaging (MRI) and plasma cytokines have been suggested as disease onset/progression biomarkers, but their ability to detect treatment efficacy is understudied. This study used the R6/2 mouse model of HD to assess if structural neuroimaging and biofluid assays can detect treatment response using as a prototype the small molecule p75NTR ligand LM11A-31, shown previously to reduce HD phenotypes in these mice. LM11A-31 alleviated volume reductions in multiple brain regions, including striatum, of vehicle-treated R6/2 mice relative to wild-types (WTs), as assessed with in vivo MRI. LM11A-31 also normalized changes in diffusion tensor imaging (DTI) metrics and diminished increases in certain plasma cytokine levels, including tumor necrosis factor-alpha and interleukin-6, in R6/2 mice. Finally, R6/2-vehicle mice had increased urinary levels of the p75NTR extracellular domain (ecd), a cleavage product released with pro-apoptotic ligand binding that detects the progression of other neurodegenerative diseases; LM11A-31 reduced this increase. These results are the first to show that urinary p75NTR-ecd levels are elevated in an HD mouse model and can be used to detect therapeutic effects. These data also indicate that multi-modal MRI and plasma cytokine levels may be effective pharmacodynamic biomarkers and that using combinations of these markers would be a viable and powerful option for clinical trials.

Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model

2015 ◽  
Vol 44 ◽  
pp. 121-127 ◽  
Author(s):  
Kuo-Hsuan Chang ◽  
Yih-Ru Wu ◽  
Yi-Chun Chen ◽  
Chiung-Mei Chen
Keyword(s):  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Inflammatory Biomarkers
Sign in / Sign up

Export Citation Format

Share Document